Related Experiment Video

Updated: Aug 6, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Is imatinib still the best choice as first-line oral TKI

Shweta Bansal1

  • 1Department of Pediatric Oncology, Asian Institute of Oncology, K J Somaiya Hospital, Sion, Mumbai, Maharashtra, India.

South Asian Journal of Cancer
|March 26, 2014
PubMed

Insights

Second and third-generation tyrosine kinase inhibitors (TKIs) offer new options for chronic myeloid leukemia (CML) treatment. However, current evidence suggests it is premature to fully transition to 2G TKIs, requiring more long-term data.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Imatinib, a tyrosine kinase inhibitor (TKI), revolutionized chronic myeloid leukemia (CML) treatment.
  • Second-generation (2G) and third-generation (3G) TKIs have since emerged, expanding therapeutic options.

Purpose of the Study:

  • To scrutinize and compare the aspects of three recommended TKIs for CML treatment.
  • To contribute to the ongoing debate regarding the optimal TKI strategy for CML management.

Main Methods:

  • Review and analysis of clinical data pertaining to Imatinib, 2G TKIs, and 3G TKIs.
  • Comparative assessment of efficacy, safety, and long-term outcomes.

Main Results:

  • While 2G and 3G TKIs offer advancements, definitive conclusions on practice-wide adoption are pending.
  • Extended observation periods are necessary to fully evaluate the long-term benefits and risks of newer TKIs.

Conclusions:

  • It is currently too early to recommend a complete shift in clinical practice towards 2G TKIs for CML.
  • Further long-term data is essential for making clear recommendations on the optimal use of next-generation TKIs in CML therapy.
Keywords:
Chronic myeloid leukemiaFrontline therapyimatinib

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
381